Pulse Biosciences announced on July 16, 2025, the appointment of Steven T. Weber as the company’s newly hired Principal Accounting Officer. This key executive addition strengthens the company's financial leadership.
Mr. Weber was granted inducement options to acquire up to 68,217 shares of common stock, with half subject to time-based vesting over four years and the other half tied to performance-based objectives, including market capitalization tranches ranging from $1.5 billion to $4.0 billion. These awards were approved and issued on July 14, 2025, with an exercise price of $16.03 per share.
The appointment of a Principal Accounting Officer is vital for ensuring robust financial controls and accurate reporting as Pulse Biosciences progresses its clinical trials and moves towards commercialization. This move reflects the company's commitment to building a comprehensive and experienced management team.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.